JP7787811B2 - ＭｒｇｐｒＸ２アンタゴニストおよびその使用 - Google Patents

ＭｒｇｐｒＸ２アンタゴニストおよびその使用

Info

Publication number
JP7787811B2
JP7787811B2 JP2022526331A JP2022526331A JP7787811B2 JP 7787811 B2 JP7787811 B2 JP 7787811B2 JP 2022526331 A JP2022526331 A JP 2022526331A JP 2022526331 A JP2022526331 A JP 2022526331A JP 7787811 B2 JP7787811 B2 JP 7787811B2
Authority
JP
Japan
Prior art keywords
compound
composition
alkyl
skin
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022526331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554392A (ja
JP2022554392A5 (https=
Inventor
フェルダ チェビクバシュ
クリストファー ピアソン
ローラ グリーブ
ニーナ コネリー ウルシニョバ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dermira Inc
Original Assignee
Dermira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermira Inc filed Critical Dermira Inc
Publication of JP2022554392A publication Critical patent/JP2022554392A/ja
Publication of JP2022554392A5 publication Critical patent/JP2022554392A5/ja
Application granted granted Critical
Publication of JP7787811B2 publication Critical patent/JP7787811B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022526331A 2019-11-05 2020-11-05 ＭｒｇｐｒＸ２アンタゴニストおよびその使用 Active JP7787811B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962931186P 2019-11-05 2019-11-05
US62/931,186 2019-11-05
US201962931576P 2019-11-06 2019-11-06
US62/931,576 2019-11-06
US202063046481P 2020-06-30 2020-06-30
US63/046,481 2020-06-30
PCT/US2020/059228 WO2021092264A1 (en) 2019-11-05 2020-11-05 MrgprX2 ANTAGONISTS AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2022554392A JP2022554392A (ja) 2022-12-28
JP2022554392A5 JP2022554392A5 (https=) 2023-10-31
JP7787811B2 true JP7787811B2 (ja) 2025-12-19

Family

ID=73740488

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526331A Active JP7787811B2 (ja) 2019-11-05 2020-11-05 ＭｒｇｐｒＸ２アンタゴニストおよびその使用

Country Status (8)

Country Link
US (1) US20230002336A1 (https=)
EP (1) EP4055011A1 (https=)
JP (1) JP7787811B2 (https=)
CN (1) CN114728919B (https=)
AU (1) AU2020380926A1 (https=)
CA (1) CA3159633A1 (https=)
IL (1) IL292693A (https=)
WO (1) WO2021092264A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115850094B (zh) * 2022-09-07 2025-02-11 北华航天工业学院 一种利用1,2-环氧丁烷合成β-氨基醇的方法
WO2025002360A1 (zh) * 2023-06-30 2025-01-02 北京普祺医药科技股份有限公司 一种mrgprx2拮抗剂、药物组合物以及其用途
WO2025042736A1 (en) 2023-08-18 2025-02-27 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
WO2025160430A1 (en) 2024-01-25 2025-07-31 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
KR20250121245A (ko) * 2024-02-02 2025-08-12 삼진제약주식회사 MRGPRX2 (Mas-related G-protein coupled receptor member X2) 길항제로서 신규 화합물 및 이를 포함하는 약학적 조성물
WO2025222040A1 (en) 2024-04-19 2025-10-23 Escient Pharmaceuticals, Inc. Mrgprx2 modulators for use in treating mrgprx2 dependent conditions in subjects with low ige
TW202547469A (zh) 2024-04-19 2025-12-16 日商杏林製藥股份有限公司 Mrgprx2拮抗劑、包含mrgprx2拮抗劑之醫藥組成物及治療mrgprx2媒介疾病或病症之方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520162A (ja) 2007-02-28 2010-06-10 スミスクライン ビーチャム コーポレーション ステアロイル−ＣｏＡデサチュラーゼ阻害剤であるチアジアゾール誘導体

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152442A (en) * 1975-06-05 1979-05-01 Lilly Industries Limited Certain acylamino-oxa (or thia) diazoles in treatment of hypersensitivity conditions
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
DE3272640D1 (en) * 1982-01-22 1986-09-18 Basf Ag Thiadiazole derivatives, process for their preparation, and their use in combatting unwanted plant growth
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
JP2006522744A (ja) * 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
GB0308511D0 (en) * 2003-04-14 2003-05-21 Astex Technology Ltd Pharmaceutical compounds
EP1658072A4 (en) * 2003-08-21 2009-03-25 Pfizer Prod Inc Compounds for the Treatment of Neurodegenerative Diseases
DE102004009933A1 (de) * 2004-02-26 2005-09-15 Merck Patent Gmbh Verwendung von Thiadiazolharnstoffderivaten
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
MX2010013705A (es) * 2008-06-13 2011-02-25 Bayer Cropscience Ag Nuevas amidas y tioamidas heteroaromaticas como plaguicidas.
WO2010073011A2 (en) * 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
US8377639B2 (en) * 2009-06-26 2013-02-19 University Of Massachusetts Compounds for modulating RNA binding proteins and uses therefor
PT2673285T (pt) * 2010-12-09 2017-10-19 Wockhardt Ltd Resumo
CA2850551A1 (en) * 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Pyridine derivatives
ES2670517T3 (es) * 2013-01-30 2018-05-30 Sumitomo Chemical Company, Limited Compuesto de amida, un agente de control de plagas de artrópodos y un método para controlar las plagas de artrópodos
EP3444251B1 (en) * 2013-12-11 2023-06-07 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
US10253023B2 (en) * 2014-10-06 2019-04-09 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
CA3055194A1 (en) * 2017-03-02 2018-09-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520162A (ja) 2007-02-28 2010-06-10 スミスクライン ビーチャム コーポレーション ステアロイル−ＣｏＡデサチュラーゼ阻害剤であるチアジアゾール誘導体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAS登録番号2373852-96-9、2373785-27-2、2372800-30-9、2305355-17-1、2072967-38-3、2072939-65-0、2072672-14-9、2072641-65-5、2072573-66-9、2072573-53-4、2072445-40-8、2072231-63-9、2072216-64-7、2072182-30-8、2072009-87-9、2071773-48-1、2071656-21-6、2071601-36-8、2071485-23-7、2071484-66-5、2071003-29-5、2069575-25-1、2069318-09-6、2069173-62-0、2068939-44-4、2068938-31-6、2068673-72-1、2060949-80-4、2059876-46-7、1797794-23-0、1795510-24-5、1389735-91-4、1355717-46-2、1087583-65-0、881939-98-6，REGISTRY（STN）[online]，2019年09月04日，[検索日 2025.02.13]
CAS登録番号380155-27-1、1355700-96-7、1957160-15-4、2179112-66-2、345614-53-1、2301679-05-8、2060999-00-8，REGISTRY（STN）[online]，2019年04月05日，[検索日 2024.09.25]

Also Published As

Publication number Publication date
JP2022554392A (ja) 2022-12-28
EP4055011A1 (en) 2022-09-14
IL292693A (en) 2022-07-01
US20230002336A1 (en) 2023-01-05
AU2020380926A1 (en) 2022-05-26
CN114728919A (zh) 2022-07-08
WO2021092264A1 (en) 2021-05-14
CN114728919B (zh) 2025-12-30
CA3159633A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
JP7712922B2 (ja) 炎症性障害を治療するためのＭｒｇｐｒＸ２アンタゴニスト
JP7827911B2 (ja) ＭｒｇｐｒＸ２アンタゴニストおよびその使用
JP7787811B2 (ja) ＭｒｇｐｒＸ２アンタゴニストおよびその使用
AU2017213475B2 (en) SecA inhibitors and methods of making and using thereof
AU2007218596A1 (en) Stabilized pharmaceutical composition
TW200404531A (en) Synergistic combinations
JP2024543413A (ja) 結晶性イミダゾ［４，５－ｂ］ピリジン化合物、医薬組成物、及び医学的状態を治療する際のそれらの使用
CN101456872A (zh) 噻唑并[3,2-a]嘧啶类衍生物及其应用
CN101500567B (zh) P38激酶抑制剂治疗精神障碍的用途
ES2637539T3 (es) Polimorfos de ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzoisoxazol-3-il]oxi}metil)piperidin-1-il]metil}-tetrahidro-2H-piran-4-carboxílico como agonistas del receptor de 5-hidroxitriptamina-4 (5-HT4) para el tratamiento de enfermedades gastrointestinales
RU2670978C9 (ru) Полиморфные формы
AU2023312830A1 (en) Methods and compounds for treating ulcerative colitis, systemic lupus erythematosus, sepsis, and post-sepsis syndrome
HK1206736B (en) Seca inhibitors and methods of making and using thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220610

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231023

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250922

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251205

R150 Certificate of patent or registration of utility model

Ref document number: 7787811

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150